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Caffeinism Associated With Greater Use of Other 
Psychotropic Agents 
John F. Greden, Andrew Procter, and Bruce Victor 
C AFFEINISM, a diagnosis recently included in the third edition of the American Psychiatric Association’s Diagnostic and Statistical Manual 
of Mental Disorders (DSM-III),’ is characterized by a constellation of affective, 
sleep, and psychophysiological manifestations.2 Because symptoms of caf- 
feinism might be confounded or masked by simultaneous ingestion of other 
drugs, it is pertinent to ask whether high consumers of caffeine differ from 
low or moderate consumers in their use of other psychoactive agents. Few 
data are currently available to answer this question. 
Historically, 18th-century physicians suggested that tea and coffee con- 
sumption promoted later use of alcohol, opium, and other stimulants.3 Such 
claims were never proven. In contrast, increased cigarette smoking has been 
conclusively associated with high caffeine consumption.4-7 Although Greden 
et al.’ noted that a greater proportion of high caffeine consumers reported use 
of minor tranquilizers when compared with low or moderate caffeine users, 
few or no studies have described patterns of use for hypnotics, neuroleptics, 
antidepressants, or lithium among subgroups of caffeine users. 
The importance of documenting possible interactions between use of caffeine 
and use of other drugs increased with several recent discoveries. First, caffeine 
was shown to interact in vitro with a number of neuroleptics to form flaky 
precipitates and thus possibly impair the efficacy of these agents.8,9 Second, 
caffeine clinically antagonizes barbiturates” and monoamine oxidase inhibitors 
(MAOI).” Third, caffeine and caffeine withdrawal have been noted to alter 
adrenergic and serotonergic transmission, and thus may interfere with ex- 
pected results from common psychiatric medications.‘.” Finally, following the 
exciting discovery that the brain contained specific receptors for benzodiaze- 
pines, it was noted that caffeine was a competitive inhibitor of diazepam 
binding to these brain receptors.‘3,‘4 Conceivably, competitive interference 
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with endogenous benzodiazepine ligands might even explain caffeine’s stim- 
ulant, anxiety-like actions. 
To assess whether use of other psychoactive agents differed among caffeine 
using subgroups, we studied 205 hospitalized patients and compared three 
subgroups of caffeine users. We observed that: (1) low, moderate and high 
caffeine-consuming subgroups differed in their use of other psychoactive sub- 
stances, specifically tobacco, minor tranquilizers, and sedative-hypnotics; (2) 
similar patterns of associated psychotropic drug use were found among psy- 
chiatric and nonpsychiatric patients, although amounts were greater in psy- 
chiatric patients; and (3) caffeine-using subgroups did not differ in their use 
of neuroleptics, antidepressants, lithium, or stimulants. This article describes 
these results in detail. 
MATERIALS AND METHODS 
Data Collection 
A 220-item questionnaire was administered to 205 hospitalized patients at the University of 
Michigan Medical Center. As described more extensively in earlier publications,7,‘5 the question- 
naire consisted of an informed consent form, demographic information, and 190 keypunchable 
items. The form determined total caffeine intake by summing caffeine ingestion from all common 
sources, including tea, coffee, cola drinks, and 25 caffeine-containing medications. We assessed 
other psychoative drug use by inquiring about frequency and quantity of each subject’s intake 
of tobacco, minor tranquilizers (benzodiazepines or meprobamate), neuroleptics, antidepressants, 
sedative-hypnotics, lithium, and stimulants. To enhance response accuracy, common pharma- 
ceutical brand names were included in the questionnaire (e.g., Valium, Thorazine, Secanol). We 
emphasize that we assessed use of caffeine and other drugs prior to hospitalization. The ques- 
tionnaire had been previously pilot tested, validated by interview, and employed in other 
studies.‘.‘5.‘6 
Subjects 
Respondents included 81 hospitalized psychiatry patients, and 124 hospitalized nonpsychiatry 
patients. The latter were operationally defined as individuals who had never received treatment 
by a psychiatrist. They conceivably could have received psychotropic agents from nonpsychiatric 
physicians. Demographic characteristics of both subgroups are illustrated in Table 1. The two 
subgroups differed significantly in sexual distribution and marital status, but not in age, race, 
religion or educational level (p > 0.05). Neither sex nor marital status have been shown to 
significantly modify caffeine intake.’ Thus, we concluded that the two subgroups could be com- 
pared with each other. Furthermore, in this study we primarily sought to evaluate drug use among 
different caffeine-consuming subgroups and studied nonpsychiatric patients mainly because many 
of the drugs we were assessing are commonly prescribed in psychiatric settings. If greater use 
of other psychoactive drugs were truly linked to caffeine use, such a pattern would need to be 
documented among nonpsychiatric as well as psychiatric patients. 
DATA ANALYSIS 
For purposes of comparing caffeine-using subgroups,’ we divided subjects 
into three categories depending upon their total caffeine intake. These in- 
cluded: (1) low consumers (O-249 mg per day); (2) moderate consumers 
(250-749 mg per day); and (3) high consumers (750 mg or more per day). Use 
of other psychotropic agents was then compared among these three subgroups. 
Chi square analysis was utilized, accepting p < 0.05 as indicating significance. 
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Table 1. Demographic Characteristics of Psychiatric and Nonpsychiatric Groups, in Percentages 
Psychiatric Nonpsychiatric 
In = 81) (n = 124) 
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* Chi square, p <O.OOl. 
t Chi square, nonsignificant at 0.05 level. 
RESULTS 
Total Caffeine Use 
When the total sample of 205 subjects was considered, 39.5% were low 
caffeine consumers, 42.5% were moderate consumers, and 18.0% ingested 
more than 750 mg caffeine per day, qualifying as high consumers. The psy- 
chiatric and nonpsychiatric subjects did not differ significantly in their caffeine 
use, although an observable trend was that 16% of the nonpsychiatric patients 
were high consumers, compared with 23% of the psychiatric patients. 
Drug Use Among Caffeine-Consuming Subgroups in the Total Sample 
Figure 1 illustrates reported use of other psychotropic drugs within the past 
month among the three caffeine-consuming subgroups. In the total sample of 
205 subjects, as caffeine use increased from low to moderate to high we noted 
a corresponding increase in the percentage using cigarettes. Specifically, 69% 
of high caffeine consumers smoked tobacco, compared to only 31% of low 
caffeine users (chi square = p < 0.001). A greater percentage of high caffeine 
users also reported use of minor tranquilizers (benzodiazepines or meproba- 
mate) within the past month, (chi square = p < 0.01). In contrast to these 
statistically-significant differences, use of stimulants, sedative hypnotics, ma- 
jor tranquilizers, antidepressants, and lithium failed to differ significantly 
among the three subgroups. 
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Fig. 1. Reported usa within past month of cigarettes, minor tranquilizers, major tranquilizers (nauro- 
laptics), antidepressants, lithium, sadativa-hypnotics, and stimulants among the thraa caffaina-consum- 
ing subgroups. 
DRUG USE AMONG CAFFEINE-CONSUMING SUBGROUPS: 
PSYCHIATRIC VS. NONPSYCHIATRIC PATIENTS 
To address the comparison between psychiatric and nonpsychiatric subjects, 
we focused upon the three drugs whose use differed most significantly in 
association with caffeine use, i.e., cigarettes, minor tranquilizers, and sedative- 
hypnotics. The use of these three agents was greater in all caffeine-using 
subgroups among psychiatric patients when compared with nonpsychiatric 
subjects (Fig. 2). Stated differently, low caffeine-consuming psychiatric pa- 
tients had more associated drug use than low caffeine-consuming nonpsy- 
chiatric patients, and similarly for moderate and high caffeine users. In both 
psychiatric and nonpsychiatric subgroups, however, the highest caffeine users 
generally also had the highest associated use of other psychoactive drugs, 
indicating this was not simply related to psychiatric patient status. 
Eighty-two percent of psychiatric patients who ingested more than 750 mg 
caffeine per day also reported smoking, seventy-one percent used minor tran- 
quilizers, and 53% reported recent use of sedative-hypnotics. The magnitude 
of these figures is noteworthy. 
When we further analyzed frequency of drug use, specifically measuring 
“occasional” use (operationally defined in the questionnaire as once a week 
or less) or “regular” use (operationally defined as twice a week or more 
frequently), patterns identical to monthly use were found. In comparison to 
nonpsychiatric patients, more high caffeine-consuming psychiatric patients 
reported occasional and regular use of sedative-hypnotics, minor tranquilizers, 
and cigarettes. Forty-one percent of psychiatric high caffeine consumers re- 
ported regular use of minor tranquilizers and 24% regular use of sedative- 
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Fig. 2. Comparison between psychiatric and nonpsychiatric patients in reported use of cigarettes, 
minor tranquilizers, and sedative-hypnotics within the past month. 
respectively. To reiterate, however, heaviest caffeine consumers-whether 
psychiatric or nonpsychiatric-had the highest use. 
DISCUSSION 
These data document for the first time that among high caffeine consumers, 
there is significantly greater use of selected other psychoactive drugs, whether 
individuals are psychiatric or nonpsychiatric patients. Most high caffeine con- 
sumers smoke extensively. The majority report recent use of benzodiazepines 
or meprobamate. Approximately half report recent use of sedative hypnotics. 
We suggest that these polydrug patterns have potential clinical implications. 
Tobacco use, for example, has been shown to complicate prescribed psy- 
chiatric treatments, partially because nicotine activates the hepatic enzyme 
system and lowers plasma levels of neuroleptics and tricyclic antidepressants.” 
High caffeine use may similarly interfere with the desired clinical effects of 
psychiatric medications by counteracting their desired effects’ or by formation 
of flaky precipitates and decreased absorption, as described previously.8*9 Since 
only combined caffeine and tobacco use has been shown to alter lipoprotein 
levels,” it is also conceivable that combined use of these two drugs could 
produce psychiatric consequences not characteristic of either drug alone. 
Assessment of this possibility is indicated. 
The finding that 65% of high caffeine users in the total sample reported use 
of minor tranquilizers within the past month has definite epidemiological sig- 
nificance. Several factors may contribute to this combined use. Heavy users, 
for example, might ingest minor tranquilizers in an attempt to counteract the 
toxic manifestations of high caffeine consumption. As previously reported,7,‘6 
the clinical picture of a person with caffeinism may be so similar to patients 
with an anxiety state that there may be diagnostic confusion. Physicians might 
then prescribe benzodiazepines rather than recommend elimination of caffeine. 
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The neurobiological mechanism underlying this pattern is probably related to 
the fact that caffeine and endogenous benzodiazepine ligands compete with 
each other for the same brain receptor sites.13,14 Thus, it would be predictable 
that as caffeine use increased, receptor competition would also increase, in- 
terfering with the “tranquilizing” effects of endogenous benzodiazepine li- 
gands and producing CNS excitation. The highest caffeine users might then 
seek to restore the balance by greater use of “exogenous” benzodiazepines, 
as observed in our study sample. This documented association raises important 
clinical concerns. If benzodiazepines are effective in minimizing symptoms 
of caffeinism, the manifestations of such a syndrome may be chronically 
masked by these drugs. The treatment of choice, in fact, ought to be reduction 
of caffeine intake, rather than adding an anxiolytic agent. Inversely, in cases 
when anxiety is due to other causes and benzodiazepines are appropriately 
prescribed, it seems likely that their efficacy might be reduced by excessive 
caffeine use, perhaps even when consumed in small quantities. This empha- 
sizes the importance of asking patients about caffeine use. Certainly, in eval- 
uating the claimed over-utilization of benzodiazepines, associated caffeine use 
should always be considered a confounding factor. Such consideration has 
been rare. 
Our finding that 24% of high caffeine consuming psychiatric patients reported 
regular use (twice per week or more) of sedative hypnotics is noteworthy. 
Analogous to the reported use of benzodiazepines, an antagonistic interaction 
is suggested. These findings support earlier observations by Forrest et al.” 
that caffeine use at bedtime counteracts sedative-hypnotics. Long-term use 
of sedative-hypnotics is clinically questionable in most patients, but in patients 
with caffeinism it would seem especially dubious. 
In contrast to differences in use of tobacco, minor tranquilizers or sedative 
hypnotics, caffeine-consuming subgroups did not differ in their reported use 
of major tranquilizers, antidepressants, or lithium. This suggests that the use 
of these latter agents primarily reflects prescribing patterns among physicians 
rather than drug-seeking behaviors among caffeine users. Another possibility 
is that caffeinism does not as frequently mimic the conditions for which 
neuroleptics, antidepressants, and lithium usually are prescribed, in contrast 
to anxiety and sleep disturbances which commonly lead to prescription of 
minor tranquilizers or sedative-hypnotics. 
Although highest caffeine consumers reported greatest use of other psy- 
chotropic agents, whether they were psychiatric or nonpsychiatric patients, 
such intake was clearly more among those receiving treatment for psychiatric 
problems. Cause and effect relationships cannot be inferred from our study 
design. We wonder whether this observed increase in use of other psychoactive 
agents among caffeine-consuming psychiatric patients is related to more fre- 
quent prescriptions of common treatments for spontaneously-occurring psy- 
chiatric problems, to relief-seeking from previously-occurring caffeinism, or 
perhaps even casually contributing to their current psychiatric status. Only 
longitudinal assessments will adequately answer these important questions. 
Hundreds of millions of persons experience the pharmacological effects of 
caffeine each day’ and a number of psychiatric implications have been iden- 
CAFFEINISM 571 
tified from such use. The drug induces a distinct clinical syndrome, i.e., 
caffeinism.‘.16 It can modify the clinical manifestations of spontaneously-oc- 
curring affective disorders.” It has been reported to precipitate or exacerbate 
psychoses.7.20*2’ Intravenous use of the drug helps reverse Parkinsonian symp- 
toms associated with neuroleptic use.22 Caffeine withdrawal syndromes are 
frequent.‘5*23 In addition to these previously-reported psychiatric effects, re- 
sults from this study suggest that high caffeine use is associated with greater 
use of various psychotropic agents. Future evaluations of these polypharmacy 
patterns are required, because with the high prevalence of such combined 
use, the clinical implications are potentially enormous. 
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